Clinical trial

SBRT Combination With rhGM-CSF and Tα1 for Stage IV NSCLC Patients Who Failed in Second-line Chemotherapy

NCT02976740

Drugs and interventions used in this trial

3 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

RADIATION · Unmapped registry intervention SBRT Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention Immunological Agent Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention Immunological Factors Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

SBRT Combination With rhGM-CSF and Tα1 for Stage IV NSCLC Patients Who Failed in Second-line Chemotherapy

Design: INTERVENTIONAL · Status: UNKNOWN · Phase: PHASE2

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusUNKNOWN

Study typeINTERVENTIONAL

Start date2016-11-01

PhasePHASE2

Conditions

Lung Cancer Metastaticunresolved

Interventions

SBRTRADIATION

Immunological AgentDRUG

Immunological FactorsDRUG

Sponsors & collaborators

The First Affiliated Hospital of Xiamen Universitylead sponsor

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT02976740 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.